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necrosis – 74,5% in 6 months observation time for each: HDR-
BT and PDR-BT method in h/n.  Serious late side-effects were 
seen in two patients (9%) - l/t and PDR-BT group.  
Conclusions: 1. HDR and PDR both had similar percentages of 
side effects. 2. Early complications due to the total radiation 
dose are frequent and needs to be treated by intensive 
pharmacology. 3. HDR or PDR are effective tools in tumor 
recurrence radiation treatment, when surgical procedure is 
impossible and using another EBRT schedule very dangerous 
for the patient.  4. Future studies should aim to determine 
the maximum tolerated dose and appropriate patient 
selection.   
Key words: head and neck cancer, HDR brachytherapy, PDR,  
recurrence, salvage treatment.   
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Purpose/Objective: Irresectable locoregional recurrent 
breast cancer in previously irradiated area is a life 
threatening disease and optimal treatment is still a matter of 
debate. Re-irradiation combined with hyperthermia 
(reRT+HT) is a valid treatment option. Four hundred and 
fourteen patients were treated with reRT+HT in the AMC 
(n=301) and the BVI (n=113), from January 1982 up to 
January 2006. We calculated response rates and local control 
(LC). Prognostic factors for tumor control were analysed in a 
multivariable analysis, with special emphasis on tumor size.  
Materials and Methods:  All patients previously received 
radiation, overlapping the current reRT field, to a median 
dose of 50Gy with or without boost. Median interval between 
initial treatment and reRT+HT was 54 months (range, 3-469). 
Most patients (80%) received one or more courses of systemic 
therapy in the past. 
The median age was 57 years at start of reRT+HT. The 
estimated tumour size was >10cm in 48% of patients (range 
0.2 – 26 cm). Distant metastases (DM) were present in 36% of 
patients and 74% had experienced previous recurrence 
episodes (range, 1-13). ReRT consisted typically of 8x4Gy, 
twice a week (AMC) or 12x3Gy, four times a week (BVI). 
Superficial hyperthermia was added once (ACM)/twice (BVI) a 
week using 434MHz Contact Flexible Microstrip Applicators. 
Aim temperature was 41-43°C for one hour. Twenty-two 
percent of patients received additional chemotherapy and 
30% additional hormone therapy. 
Results: Overall clinical response rate was 86% (58% cCR + 
28% cPR). Median follow-up (FU) 17 months. Median overall 
survival was 17 months. The 3-year LC rate was 25%. Tumor 
size, time interval to recurrence, the number of previous 
recurrent episodes, and prescence of DM were significant 
prognostic factors for LC. For patients with isolated 





Conclusions: Re-irradiation combined with hyperthermia for 
locoregional recurrence after previous irradiation results in 
high response rates of 86%, despite resistance to previous 
treatments. Overall long-term LC control was 25%, but up to 
47% in smaller tumors (< 5cm.). Tumor size, and absence of 
DM were positive prognostic factors for LC duration and 
overall survival. 
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Purpose/Objective: The outcome of current treatment of 
locally-advanced and recurrent head and neck carcinoma 
(HNC) in patients treated with radiotherapy alone is 
disappointing. The combination treatment of radiotherapy 
(RT) and cisplatin or cetuximab improves survival. Increased 
toxicity and comorbidity prohibiting combined treatment 
with cisplatin or cetuximab warrant the need for another 
radiosensitizer. Stimulated by several randomised studies 
demonstrating the radio-sensitizing effect of hyperthermia, 
we developed the HYPERcollar for applying deep 
hyperthermia in the HNC region. Here, we report the early 
experience and toxicity of deep hyperthermia treatment 
combined with radiotherapy in a cohort of patients with 
advanced HNC. 
Materials and Methods: In total, 119 hyperthermia 
treatments given to 27 patients, treated with advanced HNC, 
were included in this analysis. Hyperthermia was applied for 
60 minutes, or later 75 minutes, depending on patients’ 
tolerance using the HYPERcollar, aimed at achieving 43°C in 
the target region. Treatment quality was monitored by 
patient specific hyperthermia pre-treatment planning 
combined with real-time invasive thermometry if possible, or 
pre-treatment planning alone. RT was given using either 
external beam irradiation (Cyberknife or IMRT) or interstitial 
irradiation. 
Results: Applying hyperthermia in the very well perfused 
head and neck region proved to be challenging and high 
power levels were required (median 543W). 13% of the 
hyperthermia treatments were not fully completed, mostly 
due to pain (5%), which we allocated to hyperthermia 
treatment and dyspnoea (2%) caused by sticky saliva, 
associated with irradiation. Mean hyperthermia treatment 
time was 94% of planned duration. No severe complications 
or enhanced thermal or mucosal toxicities were observed. 
Preferably, metal implants (>1cm) should be removed to 
minimize the risk of toxicity, and prevent any unpredictable 
resonances reducing the predictive value of treatment 
